NCT02954874 2026-03-17
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
SWOG Cancer Research Network
City of Hope Medical Center
National Cancer Institute (NCI)